<DOC>
	<DOC>NCT00559221</DOC>
	<brief_summary>- To determine the feasibility of fludarabine and cytarabine as continuous infusion plus idarubicin with granulocyte-colony stimulating factor priming for patients with resistant acute myeloid leukemia other than acute promyelocytic leukemia</brief_summary>
	<brief_title>FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML</brief_title>
	<detailed_description>- The feasibility will be evaluated in terms of toxicities, complete remission rate, duration of complete remission, disease-free survival, and overall survival.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Failure to achieve CR after initial induction chemotherapy including standard dose cytarabine. Early relapse, occurring after a first CR lasting less than 12 months. Patients with multiple relapses will be included. Written informed consent must be given. 15 and 60 years of age. 2 or less by ECOG performance scale. acute promyelocytic leukemia pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>AML</keyword>
</DOC>